Trends in MacTel treatment: A vascular or neurological disease?
Open Access
- 6 July 2019
- journal article
- Published by Peertechz Publications Private Limited in Journal of Clinical Research and Ophthalmology
- Vol. 6 (1), 025-027
- https://doi.org/10.17352/2455-1414.000059
Abstract
No abstract availableThis publication has 26 references indexed in Scilit:
- Reduced-Fluence Photodynamic Therapy Combined with Ranibizumab for Nonproliferative Macular Telangiectasia Type 2Ophthalmologica, 2013
- Conditional Müller Cell Ablation Causes Independent Neuronal and Vascular Pathologies in a Novel Transgenic ModelJournal of Neuroscience, 2012
- EFFICACY OF ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN SUBRETINAL NEOVASCULARIZATION SECONDARY TO MACULAR TELANGIECTASIA TYPE 2Retina, 2012
- Identification of a Potential Susceptibility Locus for Macular Telangiectasia Type 2PLOS ONE, 2012
- TREATMENT OF NONNEOVASCULAR IDIOPATHIC MACULAR TELANGIECTASIA TYPE 2 WITH INTRAVITREAL RANIBIZUMABRetina, 2012
- Comparison Between Efficacy of Triamcinolone Acetonide and Bevacizumab in a Case with Type 2A Idiopathic Parafoveal TelangiectasiaTürk Oftalmoloji Dergisi, 2011
- Perifoveal Müller Cell Depletion in a Case of Macular Telangiectasia Type 2Ophthalmology, 2010
- MACULAR TELANGIECTASIARetina, 2010
- Transpupillary thermotherapy for subfoveal neovascularization secondary to group 2A idiopathic juxtafoveolar telangiectasisAmerican Journal of Ophthalmology, 2004
- Adenovirus-Mediated Gene Transfer of Ciliary Neurotrophic Factor Can Prevent Photoreceptor Degeneration in the Retinal Degeneration (rd) MouseHuman Gene Therapy, 1997